Gen-Probe Buys UK Diagnostics Company

Xconomy San Diego — 

San Diego-based Gen-Probe (NASDAQ: GPRO) says it’s buying Tepnel Life Sciences, a British medical diagnostics company, for about $132.2 million. Gen-Probe chairman and CEO Hank Nordoff says the buyout expands Gen-Probe’s focus on nucleic acid tests by adding Tepnel’s expertise in genetic tests for cystic fibrosis, Down syndrome and inherited levels of high cholesterol. Gen-Probe’s tests are used mostly to screen human blood donations and diagnose human diseases.